Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2021 Mar 9;7(2):e572.
doi: 10.1212/NXG.0000000000000572. eCollection 2021 Apr.

Associations Between Variant Repeat Interruptions and Clinical Outcomes in Myotonic Dystrophy Type 1

Stephan Wenninger  1 , Sarah A Cumming  1 , Kristina Gutschmidt  1 , Kees Okkersen  1 , Aura Cecilia Jimenez-Moreno  1 , Ferroudja Daidj  1 , Hanns Lochmüller  1 , Fiona Hogarth  1 , Hans Knoop  1 , Guillaume Bassez  1 , Darren G Monckton  1 , Baziel G M van Engelen  1 , Benedikt Schoser  1
Affiliations

Associations Between Variant Repeat Interruptions and Clinical Outcomes in Myotonic Dystrophy Type 1

Stephan Wenninger et al. Neurol Genet. .

Abstract

Objective: To assess the association between variant repeat (VR) interruptions in patients with myotonic dystrophy type 1 (DM1) and clinical symptoms and outcome measures after cognitive behavioral therapy (CBT) intervention.

Methods: Adult patients with DM1 were recruited within the OPTIMISTIC trial (NCT02118779). Disease-related history, current clinical symptoms and comorbidities, functional assessments, and disease- and health-related questionnaires were obtained at baseline and after 5 and 10 months. After genetic analysis, we assessed the association between the presence of VR interruptions and clinical symptoms' long-term outcomes and compared the effects of CBT in patients with and without VR interruptions. Core trial outcome measures analyzed were: 6-minute walking test, DM1-Activ-C, Checklist Individual Strength Fatigue Score, Myotonic Dystrophy Health Index, McGill-Pain questionnaire, and Beck Depression inventory-fast screen. Blood samples for DNA testing were obtained at the baseline visit for determining CTG length and detection of VR interruptions.

Results: VR interruptions were detectable in 21/250 patients (8.4%)-12 were assigned to the standard-of-care group (control group) and 9 to the CBT group. Patients with VR interruptions were significantly older when the first medical problem occurred and had a significantly shorter disease duration at baseline. We found a tendency toward a milder disease severity in patients with VR interruptions, especially in ventilation status, mobility, and cardiac symptoms. Changes in clinical outcome measures after CBT were not associated with the presence of VR interruptions.

Conclusions: The presence of VR interruptions is associated with a later onset of the disease and a milder phenotype. However, based on the OPTIMISTIC trial data, the presence of VR interruptions was not associated with significant changes on outcome measures after CBT intervention.

Trial registration information: ClinicalTrials.gov NCT02118779.

PubMed Disclaimer

Figures

Figure 1
Figure 1. Age at Symptom Onset and at Baseline in Patients With Variant Repeats (VR+) and Without Variant Repeats (VR−)
Figure 2
Figure 2. Muscular Impairment Rating Scale (MIRS) at Baseline and Visit 4 in Patients With Variant Repeats (VR+) and Without Variant Repeats (VR−) in % of the Subgroup
Figure 3
Figure 3. Core Outcome Measures for the 4 Subgroups for the 6MWT (A), DM1-Activ-c Score (B), Checklist Individual Strength, Subscore Fatigue (CIS-Fatigue) Score (C), and the Myotonic Dystrophy Health Index (MDHI) (D)
Higher values in 6MWT and DM1-Activ-c, and lower values in CIS-fatigue and MDHI indicate improvement. 6MWT = 6-minute walking test; DM1 = myotonic dystrophy type 1.
See this image and copyright information in PMC

References

    1. Harley HG, Brook JD, Rundle SA, et al. Expansion of an unstable DNA region and phenotypic variation in myotonic dystrophy. Nature 1992;355:545–546. - PubMed
    1. Harley HG, Rundle SA, MacMillan JC, et al. Size of the unstable CTG repeat sequence in relation to phenotype and parental transmission in myotonic dystrophy. Am J Hum Genet 1993;52:1164–1174. - PMC - PubMed
    1. Morales F, Couto JM, Higham CF, et al. Somatic instability of the expanded CTG triplet repeat in myotonic dystrophy type 1 is a heritable quantitative trait and modifier of disease severity. Hum Mol Genet 2012;21:3558–3567. - PubMed
    1. Marchini C, Lonigro R, Verriello L, Pellizzari L, Bergonzi P, Damante G. Correlations between individual clinical manifestations and CTG repeat amplification in myotonic dystrophy. Clin Genet 2000;57:74–82. - PubMed
    1. Mladenovic J, Pekmezovic T, Todorovic S, et al. Survival and mortality of myotonic dystrophy type 1 (Steinert's disease) in the population of Belgrade. Eur J Neurol 2006;13:451–454. - PubMed

Associated data